Ginkgo Bioworks Holdings Inc Financials
Ginkgo Bioworks Holdings Inc (DNA) reported $170.2M in revenue for fiscal year 2025, down 25.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A shrinking revenue base is being matched by deep expense reductions, but negative cash generation still defines the operating model.
In FY2025, operating cash flow was-$171M against an operating loss of$315M ; noncash charges soften the accounting loss, but do not make operations cash-positive. Free cash flow was-$179M , only modestly below operating cash flow, indicating that capital spending is not the main source of cash consumption.
Revenue contracted
Debt-to-equity rose to 1.2x even as total liabilities fell
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ginkgo Bioworks Holdings Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Ginkgo Bioworks Holdings Inc, and counted as zero in the overall score.
Not available for Ginkgo Bioworks Holdings Inc, and counted as zero in the overall score.
Ginkgo Bioworks Holdings Inc scores -7.57, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($507.7M) relative to total liabilities ($611.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ginkgo Bioworks Holdings Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Ginkgo Bioworks Holdings Inc reported a net loss of $313K while operations used $171.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ginkgo Bioworks Holdings Inc generated $170.2M in revenue in fiscal year 2025. This represents a decrease of 25.1% from the prior year.
Ginkgo Bioworks Holdings Inc's EBITDA was -$256.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 48.4% from the prior year.
Ginkgo Bioworks Holdings Inc reported -$313K in net income in fiscal year 2025. This represents an increase of 42.8% from the prior year.
Ginkgo Bioworks Holdings Inc earned -$5.64 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Ginkgo Bioworks Holdings Inc recorded an outflow of $178.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 53.2% from the prior year.
Ginkgo Bioworks Holdings Inc held $167.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Ginkgo Bioworks Holdings Inc's net profit margin was -0.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.1 percentage points from the prior year.
Ginkgo Bioworks Holdings Inc's ROE was -0.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Ginkgo Bioworks Holdings Inc invested $243.8M in research and development in fiscal year 2025. This represents a decrease of 42.5% from the prior year.
Ginkgo Bioworks Holdings Inc invested $7.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 87.7% from the prior year.
Not reported for fiscal year 2025.
DNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $132.4M | $170.2M-25.1% | $227.0M-9.7% | $251.5M-47.4% | $477.7M+52.2% | $313.8M+309.4% | $76.7M+41.5% | $54.2M |
| R&D Expenses | $215.6M | $243.8M-42.5% | $424.1M-27.0% | $580.6M-44.8% | $1.1B-8.4% | $1.1B+619.6% | $159.8M+65.9% | $96.3M |
| SG&A Expenses | $177.2M | $183.3M-25.5% | $246.2M-36.1% | $385.0M-73.1% | $1.4B+65.7% | $863.0M+2152.8% | $38.3M+29.9% | $29.5M |
| Operating Income | -$306.1M | -$315.3M+43.7% | -$559.8M+35.2% | -$864.4M+60.9% | -$2.2B-20.8% | -$1.8B-1234.4% | -$137.0M-91.4% | -$71.6M |
| Interest Expense | -$5.3M | $0-100.0% | $94K+1.1% | $93K-12.3% | $106K-95.5% | $2.4M-0.5% | $2.4M-1.5% | $2.4M |
| Income Tax | -$594K | -$837K-74.7% | -$479K-574.6% | -$71K+99.5% | -$15.0M-915.3% | -$1.5M-178.3% | $1.9M+8486.4% | $22K |
| Net Income | $21.6M | -$313K+42.8% | -$547K+38.7% | -$893K+57.6% | -$2.1M-15.0% | -$1.8M+98.6% | -$126.6M-6.1% | -$119.3M |
| EPS (Diluted) | — | -$5.64 | -$0.01+42.9% | -$0.02 | -$0.05 | -$1.39 | -$0.100.0% | -$0.10 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B-18.7% | $1.4B-17.3% | $1.7B-34.4% | $2.5B+22.6% | $2.1B+206.7% | $675.2M-3.2% | $697.3M |
| Current Assets | $471.8M-21.7% | $602.7M-39.8% | $1.0B-30.9% | $1.5B-15.8% | $1.7B+304.0% | $426.5M-16.7% | $511.9M |
| Cash & Equivalents | $167.2M-70.2% | $561.6M-40.5% | $944.1M-28.3% | $1.3B-15.1% | $1.6B+307.0% | $380.8M-23.1% | $495.3M |
| Inventory | N/A | N/A | $46K-98.9% | $4.4M+29.8% | $3.4M+22.9% | $2.7M | $0 |
| Accounts Receivable | $24.0M+9.9% | $21.9M+27.4% | $17.2M-78.8% | $80.9M-38.5% | $131.5M+688.0% | $16.7M+382.3% | $3.5M |
| Goodwill | N/A | $0-100.0% | $49.2M-18.2% | $60.2M+182.5% | $21.3M+1047.7% | $1.9M0.0% | $1.9M |
| Total Liabilities | $611.1M-7.6% | $661.4M+16.4% | $568.2M-29.2% | $803.0M+59.5% | $503.6M+145.5% | $205.1M+4.9% | $195.5M |
| Current Liabilities | $96.0M-10.5% | $107.3M-34.5% | $163.9M-5.3% | $173.0M+28.3% | $134.8M+84.0% | $73.2M+82.7% | $40.1M |
| Total Equity | $508.6M-29.0% | $716.1M-34.7% | $1.1B-36.8% | $1.7B+15.3% | $1.5B+226.3% | $461.4M-6.4% | $493.1M |
| Retained Earnings | -$6.2B-5.4% | -$5.8B-10.3% | -$5.3B-20.3% | -$4.4B-91.4% | -$2.3B-391.1% | -$467.9M-37.1% | -$341.3M |
Not reported in any period shown, so not listed: Long-Term Debt.
DNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$170.2M | -$171.1M+46.5% | -$319.6M-8.2% | -$295.5M-17.2% | -$252.2M+0.6% | -$253.8M-86.9% | -$135.8M-204.1% | -$44.7M |
| Capital Expenditures | $4.6M | $7.7M-87.7% | $62.5M+53.3% | $40.8M-21.9% | $52.3M-7.5% | $56.5M-2.2% | $57.8M+160.2% | $22.2M |
| Free Cash Flow | -$174.8M | -$178.7M+53.2% | -$382.1M-13.6% | -$336.3M-10.5% | -$304.5M+1.9% | -$310.3M-60.3% | -$193.7M-189.5% | -$66.9M |
| Investing Cash Flow | $56.5M | -$240.3M-286.1% | -$62.2M+22.9% | -$80.7M-19.7% | -$67.4M+8.0% | -$73.3M-9.1% | -$67.1M+10.0% | -$74.6M |
| Financing Cash Flow | $34.5M | $17.8M+1122.1% | -$1.7M+45.9% | -$3.2M-103.4% | $95.3M-93.8% | $1.5B+1598.6% | $90.3M-78.0% | $410.4M |
| Dividends Paid | N/A | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0-100.0% | $25.0M | $0-100.0% | $408K |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Net Margin | -0.2%+0.1pp | -0.2%+0.1pp | -0.4%+0.1pp | -0.4%+0.1pp | -0.6% | -165.2% | -220.2% |
| Return on Equity | -0.1%0.0pp | -0.1%0.0pp | -0.1%0.0pp | -0.1%0.0pp | -0.1%+27.3pp | -27.4%-3.2pp | -24.2% |
| Return on Assets | 0.0%0.0pp | 0.0%0.0pp | -0.1%0.0pp | -0.1%0.0pp | -0.1%+18.7pp | -18.8%-1.6pp | -17.1% |
| Current Ratio | 4.92-0.7x | 5.62-0.5x | 6.11-2.3x | 8.38-4.4x | 12.79+7.0x | 5.83-6.9x | 12.77 |
| Debt-to-Equity | 1.20+0.3x | 0.92+0.4x | 0.52+0.1x | 0.46+0.1x | 0.33-0.1x | 0.440.0x | 0.40 |
| FCF Margin | -105.0% | -168.3% | -133.7% | -63.7%+35.2pp | -98.9% | -252.6% | -123.4% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Ginkgo Bioworks Holdings Inc Ranks
Frequently Asked Questions
What is Ginkgo Bioworks Holdings Inc's annual revenue?
Ginkgo Bioworks Holdings Inc (DNA) reported $170.2M in total revenue for fiscal year 2025. This represents a -25.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ginkgo Bioworks Holdings Inc's revenue growing?
Ginkgo Bioworks Holdings Inc (DNA) revenue declined by 25.1% year-over-year, from $227.0M to $170.2M in fiscal year 2025.
Is Ginkgo Bioworks Holdings Inc profitable?
No, Ginkgo Bioworks Holdings Inc (DNA) reported a net income of -$313K in fiscal year 2025, with a net profit margin of -0.2%.
What is Ginkgo Bioworks Holdings Inc's EBITDA?
Ginkgo Bioworks Holdings Inc (DNA) had EBITDA of -$256.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ginkgo Bioworks Holdings Inc's net profit margin?
Ginkgo Bioworks Holdings Inc (DNA) had a net profit margin of -0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ginkgo Bioworks Holdings Inc's return on equity (ROE)?
Ginkgo Bioworks Holdings Inc (DNA) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ginkgo Bioworks Holdings Inc's free cash flow?
Ginkgo Bioworks Holdings Inc (DNA) recorded an outflow of $178.7M in free cash flow during fiscal year 2025. This represents a 53.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ginkgo Bioworks Holdings Inc's operating cash flow?
Ginkgo Bioworks Holdings Inc (DNA) recorded an outflow of $171.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Ginkgo Bioworks Holdings Inc's total assets?
Ginkgo Bioworks Holdings Inc (DNA) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ginkgo Bioworks Holdings Inc's capital expenditures?
Ginkgo Bioworks Holdings Inc (DNA) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ginkgo Bioworks Holdings Inc spend on research and development?
Ginkgo Bioworks Holdings Inc (DNA) invested $243.8M in research and development during fiscal year 2025.
What is Ginkgo Bioworks Holdings Inc's current ratio?
Ginkgo Bioworks Holdings Inc (DNA) had a current ratio of 4.92 as of fiscal year 2025, which is generally considered healthy.
What is Ginkgo Bioworks Holdings Inc's debt-to-equity ratio?
Ginkgo Bioworks Holdings Inc (DNA) had a debt-to-equity ratio of 1.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ginkgo Bioworks Holdings Inc's return on assets (ROA)?
Ginkgo Bioworks Holdings Inc (DNA) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ginkgo Bioworks Holdings Inc's Altman Z-Score?
Ginkgo Bioworks Holdings Inc (DNA) has an Altman Z-Score of -7.57, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ginkgo Bioworks Holdings Inc's Piotroski F-Score?
Ginkgo Bioworks Holdings Inc (DNA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ginkgo Bioworks Holdings Inc's earnings high quality?
Ginkgo Bioworks Holdings Inc (DNA) reported a net loss of $313K while operations used $171.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ginkgo Bioworks Holdings Inc?
Ginkgo Bioworks Holdings Inc (DNA) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.